Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — H1 FY2019 Earnings Presentation

14 slides from Jcr Pharmaceuticals's earnings presentation, Nov 6, 2019

1. Slide 1: FY2019 First-Half Results Briefing Session

   FY2019 First-Half results Briefing Session Financial Results - Six Months Ended Sep.30, 2019 (2Q FY2019) - November 6, 2019 JCR Pharmaceuticals co., Ltd. 【Securities code】 4552, 1st Sec. TSE Copyright © 2019 JCR Pharmaceuticals Co., Ltd. All rights reserved.

2. Slide 2: Consolidated Results

   Consolidated Results (Unit: Million yen) Six Months Ended FY2019 Sep. 30, 2019 (Apr. 1, 2019- Mar. 31, 2020) Six Months Ended Consolidated Expected Sep.30, 2018 Initial Forecast A Year-on-Year progress rate B A/B Net Sales 10,275 11,236 9.3% 26,400 42.6% Cost of Sales 2,995 3,173 5.9% 7,300 43.5% Gr

3. Slide 3: Sales by Business Segments (Consolidated)

   Sales by business Segments (Consolidated) (Unit: Million yen) Six Months Ended Six Months Ended FY2019 Reference Sep. 30, 2018 Sep. 30 2019 (Apr. 1, 2019- Mar. 31, 2020) Number of business segment Composition Composition Forecast Expected Forecast ratio A ratio Year-on-Year (after fixing) progress r

4. Slide 4: Transition in Sales by Business Segments (Consolidated)

   Transition in Sales by business Segments (Consolidated) 110 (Unit: Million yen) 2,506 65 1,002 210 192 257 9 123 512 663 354 1,054 74 817 1,527 Other 1,625 27 558 License Revenue 228 1,052 989 17 Urine-derived products 828 958 725 586 Agalsidase Beta BS 427 317 TEMCELL 261 Epoetin Alpha BS 2,272 2,3

5. Slide 5: Year-on-year changes

   Year-on-year changes ◆ Net sales 11,236 million yen, year-on-year +960 million yen (Unit: Million yen) Six Months Ended Sep. 30, 2018 10,275 Growject +390 Epoetin Alpha BS +105 Main increase/decrease TEMCELL +537 ・ Growject ＋390 million yen ・ TEMCELL ＋537 million yen Agalsidase Beta BS +123 ・ Licens

6. Slide 6: Balance Sheets (Consolidated)

   Balance Sheets (Consolidated) （Unit: Million yen） Mar. Sep. Main Mar. Sep. Main 2019 2019 increase/decrease 2019 2019 increase/decrease Cash and deposit Short-term loans ＋2,176 payable Notes and accounts Current ＋1,350 liabilities 8,684 9,686 Income taxes receivable-trade Current payable assets 27,3

7. Slide 7: Transition in Balance Sheets (Consolidated)

   Transition in Balance Sheets (Consolidated) (Unit: Million yen) Assets Liabilities and net assets Investments and other assets Current liabilities Non-current liabilities Intangible assets Total net assets Property, plant and equipement Equity ratio 75.9% 75.0% Current assets 70.3% 71.8% 71.1% 66.9%

8. Slide 8: Cash Flows (Consolidated)

   Cash Flows (Consolidated) （Unit: Million yen） Six Months Six Months Operating Activities Ended Ended Year-on-year investing Activities Sep.30, 2018 Sep.30, 2019 Ｂ-Ａ A B Financing Activities Cash and Cash Equivalents at End of Period Income before income taxes 1,855 1,098 (757) Depreciation and amort

9. Slide 9: Transition in Cash Flows (Consolidated)

   Transition in Cash Flows (Consolidated) （Unit: Million yen） FY2015 FY2015 FY2016 FY2016 FY2017 FY2017 FY2018 FY2018 FY2019 1stH 2ndH 1stH 2ndH 1stH 2ndH 1stH 2ndH 1stH Operating Activities 3,093 3,093 △(892) 892 1,909 1,909 742 742 1,830 1,830 1,303 1,303 2,372 2,372 1,533 1,533 2,949 2,949 Investin

10. Slide 10: Transition in Gross Profit Margin

    Transition in Gross profit margin (Unit: Million yen) Product sales License Revenue Gross profit margin (Product sales) Gross profit margin (including License Revenue) 73.7% 72.3% 70.8% 71.8% 69.9% 66.9% 66.8% 59.4% 69.0% 67.1% 68.7% 67.5% 64.9% 65.1% 65.6% 58.9% 2,506 1,002 512 1,054 558 1,625 116

11. Slide 11: Transition in Composition Ratio of Cost/Expense

    Transition in composition ratio of cost/expense Operating Income R&D Expenses SG&A Cost of Sales 29.8% 29.2% 28.4% 28.2% 31.7% 37.0％ 6,128 2,995 6,567 3,173 5,731 6,459 31.4% 33.9% 31.4% 34.2% 32.7% 31.5％ 6,469 7,270 3,809 Above number（％） 3,510 rate of sales 5,919 Lower number 5,477 (Million yen) Am

12. Slide 12: Correlation between R&D Expenses and Main R&D Pipeline

    Correlation between R&D expenses and main R&D pipeline (Unit: Million yen) Preclinical R&D expenses (before deduction) Clinical Filed an application Approved 3,539 2,620 2,707 2,863 2,158 2,407 1,833 1,726 1,931 FY2015 FY2015 FY2016 FY2016 FY2017 FY2017 FY2018 FY2018 FY2019 1stH 2ndH 1stH 2ndH 1stH

13. Slide 13: Forward-Looking Statement

    FORWARD- LOOKING STATEMENT This presentation contains, and answers given to questions that may be asked today may constitute, forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward-looking statements regarding our plans,

14. Slide 14: Copyright © 2019 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2019 JCR Pharmaceuticals Co., Ltd. All rights reserved.

JCR Pharmaceuticals — H1 FY2019 Earnings Presentation on 6ix